Cholesterol Lowering and Residual Risk in Diabetes, Type 1

• Status: Recruiting
• Trial end date: 2027-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question.

This study will recruit 125 participants with Type 1 Diabetes (T1D) to:

1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal

2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and

3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NYU Langone Health
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Atorvastatin; Calcium; Evolocumab; Ezetimibe

Criteria

Inclusion Criteria:

1. Participants with previous diagnosis of T1D (as defined by American Diabetes Association or judgment of physician for at least 1 year)

1. American Diabetes Association Criteria for diagnosis of diabetes (Must meet at least 1 of the following criteria):

• i. FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 hours, OR;

• ii. 2-h PG ≥200 mg/dL (11.1 mmol/L) during OGTT. The test should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water, OR;

• iii. A1C ≥6.5% (48 mmol/mol), OR;

• iv. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L), AND;

2. History of T1D (due to autoimmune β-cell destruction, usually leading to absolute insulin deficiency, including latent autoimmune diabetes of adulthood). Autoimmune markers include islet cell autoantibodies and autoantibodies to GAD (glutamic acid decarboxylase, GAD65), insulin, the tyrosine phosphatases islet antigen 2 (IA-2) and IA-2β, and zinc transporter 8, OR;

3. Diagnosis of T1D and confirmed by review of records by 2 separate clinical members of the study team

2. Age ≥ 18 & < 90

3. LDL-C >100mg/dl

4. Able and willing to provide written informed consent for the study

Exclusion Criteria:

1. Established cardiovascular disease on antithrombotic therapy

2. Triglycerides >400mg/dl

3. Use of a PCSK9 inhibitor

4. Recent infection in the past 30 days

5. Any hospitalization in the past 30 days

6. Use of immunosuppressive therapy

7. Use of any antithrombotic therapy

8. Use of aspirin

9. Use of NSAID within the past 72 hours

10. Pregnancy

11. Anemia (hemoglobin < 9 g/dl) or thrombocytopenia (platelet count <75), or thrombocytosis (platelet count >600)

12. A history of hemorrhagic diathesis

13. Chronic kidney disease (CrCl < 30ml/min)

14. T2D, monogenic diabetes syndromes, or diabetes in the context of disease of the exocrine pancreas (such as pancreatitis, trauma or pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis)